Summary
Blackstone, a leading private equity firm, has announced the closure of a new $6.3 billion fund dedicated to investing in the life sciences sector. The fund, named Blackstone Life Sciences V, is the largest fund dedicated to life sciences investing ever raised by a private equity firm. The announcement was made on July 1, 2021.
Access impact
The closure of this new fund has significant implications for the life sciences industry, particularly in terms of pricing, reimbursement, and health technology assessment (HTA). With access to such a large pool of capital, Blackstone will have the means to make substantial investments in biopharma assets, potentially leading to higher prices for innovative therapies. This may also impact HTA decisions, as payers and HTA bodies will need to carefully consider the cost-effectiveness and value of these investments in light of rising healthcare costs.
Top-3 domain lens
Cost-Effectiveness
The new fund has the potential to drive up the cost of innovative therapies, as Blackstone invests in promising biopharma assets. This could have a significant impact on the cost-effectiveness of these therapies and may raise concerns for payers and HTA bodies.
Evidence Quality and Robustness
With a large pool of capital at their disposal, Blackstone will likely invest in a variety of biopharma assets, ranging from early-stage research to late-stage development. This may lead to a lack of robust evidence for these therapies, making it difficult for payers and HTA bodies to make informed decisions on their value and cost-effectiveness.
Budget Impact and Resources
The closure of this new fund may also have a significant impact on healthcare budgets, as Blackstone invests in high-priced biopharma assets. Payers and HTA bodies will need to carefully consider the budget impact of these investments and ensure that resources are being used effectively to fund access to innovative therapies.
Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug
CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source
source: https://www.biopharmadive.com/news/blackstone-life-sciences-investing-private-equity-largest-fund/816128/